Q1 2023 Results

Company overview Financial review Conclusions Appendix References Conclusions Strong start to 2023: Growth particularly driven by EntrestoⓇ, KisqaliⓇ and KesimptaⓇ Launches: PluvictoⓇ and ScemblixⓇ continue strong trajectory, LeqvioⓇ progresses steadily Confidence in near- to mid-term growth: NATALEE Phase 3 positive readout, upcoming iptacopan data, and PluvictoⓇ in earlier lines of therapy Raising guidance: Strong start and confidence in growth drivers allow to raise FY 2023 guidance. 30 Investor Relations | Q1 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation